World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: JPRN
Last refreshed on: 2 April 2019
Main ID:  JPRN-C000000374
Date of registration: 01/04/2006
Prospective Registration: No
Primary sponsor: The Japanese Pediatric IgA Nephropathy of Treatment Study Group
Public title: A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.
Scientific title:
Date of first enrolment: 1998/08/01
Target sample size: 20
Recruitment status: Complete: follow-up complete
URL:  https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000468
Study type:  Interventional
Study design:  Single arm Non-randomized  
Phase:  Not selected
Countries of recruitment
Japan
Contacts
Name: Koichi Nakanishi   
Address:  811-1 Kimiidera Wakayama City Wakayama Japan
Telephone:
Email:
Affiliation:  The Japanese Pediatric IgA Nephropathy of Treatment Study Group Department of Pediatrics, Wakayama Medical University
Name: Norishige Yoshikawa   
Address:  811-1 Kimiidera Wakayama City Wakayama Japan
Telephone:
Email:
Affiliation:  Wakayama Medical University Department of Pediatrics
Key inclusion & exclusion criteria
Inclusion criteria: 1.Newly biopsy proven IgA nephropathy with diffuse mesangial proliferation
2.Aged 2 to 18 years
3.Written informed consent from the patients' parents or legal guardians

Exclusion criteria: 1.Nephrotic syndrome
2.Systemic diseases defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus, etc)
3.Medical history of allergy or hypersensitivity reactions to prednisolone, warfarin or dipyridamole
3.Chronic renal dysfunction
4.Active infectious disease
5.Severe liver disfunction
6.History of corticosteroid and immunosupression administration
7.Pregnancy
8.Judged inappropriate for this study by the physicians


Age minimum: 2years-old
Age maximum: 18years-old
Gender: Male and Female
Health Condition(s) or Problem(s) studied
IgA nephropathy in children
Intervention(s)
prednisolone+warfarin+dipyridamole for 2 years
Primary Outcome(s)
Disappearance rate of proteinuria
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
The Kidney Foundation, Japan
Secondary Sponsor(s)
Ethics review
Status:
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history